Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to -$97.5 million.

  • IDEAYA Biosciences' Cash from Investing Activities rose 5052.18% to -$97.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $70.0 million, marking a year-over-year increase of 11392.39%. This contributed to the annual value of $70.0 million for FY2025, which is 11392.39% up from last year.
  • According to the latest figures from Q4 2025, IDEAYA Biosciences' Cash from Investing Activities is -$97.5 million, which was up 5052.18% from $41.8 million recorded in Q3 2025.
  • Over the past 5 years, IDEAYA Biosciences' Cash from Investing Activities peaked at $79.8 million during Q1 2025, and registered a low of -$354.0 million during Q1 2024.
  • In the last 5 years, IDEAYA Biosciences' Cash from Investing Activities had a median value of -$14.0 million in 2022 and averaged -$34.7 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Cash from Investing Activities plummeted by 238813.56% in 2022, and later surged by 37483.27% in 2023.
  • IDEAYA Biosciences' Cash from Investing Activities (Quarter) stood at -$413000.0 in 2021, then plummeted by 2388.14% to -$10.3 million in 2022, then plummeted by 989.36% to -$111.9 million in 2023, then tumbled by 76.08% to -$197.1 million in 2024, then soared by 50.52% to -$97.5 million in 2025.
  • Its Cash from Investing Activities was -$97.5 million in Q4 2025, compared to $41.8 million in Q3 2025 and $45.9 million in Q2 2025.